|
JPS509164A
(enExample)
|
1973-05-11 |
1975-01-30 |
|
|
|
IL64573A
(en)
|
1980-12-18 |
1985-04-30 |
Wellcome Found |
Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them
|
|
AU576322B2
(en)
|
1983-07-22 |
1988-08-25 |
Ici Australia Limited |
Alpha-substituted-alpha-cyanomethyl alcohols
|
|
US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
|
JPH05255106A
(ja)
|
1990-10-31 |
1993-10-05 |
Toray Ind Inc |
血小板減少症治療剤
|
|
JPH059164A
(ja)
|
1991-07-02 |
1993-01-19 |
Sumitomo Chem Co Ltd |
光学活性マンデロニトリル誘導体の製造方法
|
|
GB9217331D0
(en)
|
1992-08-14 |
1992-09-30 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US6096786A
(en)
|
1992-10-01 |
2000-08-01 |
Glaxo Wellcome Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
US5872151A
(en)
|
1992-10-01 |
1999-02-16 |
Glaxo Wellcome Inc. |
Immunopotentiatory agents and physiologically acceptable salts thereof
|
|
DK0609606T3
(enExample)
|
1992-10-01 |
1997-03-17 |
Wellcome Found |
|
|
DK0674510T3
(da)
|
1992-11-27 |
1999-05-10 |
Napro Biotherapeutics Inc |
Injicerbart præparat omfattende paclitaxel
|
|
JPH0725858A
(ja)
|
1993-07-13 |
1995-01-27 |
Otsuka Pharmaceut Co Ltd |
ピペラジン誘導体
|
|
US5958980A
(en)
|
1993-08-26 |
1999-09-28 |
Glaxo Wellcome, Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
IL110787A0
(en)
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
|
GB9402807D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9402809D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9426224D0
(en)
|
1994-12-23 |
1995-02-22 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5891877A
(en)
|
1995-02-14 |
1999-04-06 |
Xenova Limited |
Pharmaceutical compounds
|
|
US5874443A
(en)
|
1995-10-19 |
1999-02-23 |
Trega Biosciences, Inc. |
Isoquinoline derivatives and isoquinoline combinatorial libraries
|
|
US5886210A
(en)
|
1996-08-22 |
1999-03-23 |
Rohm And Haas Company |
Method for preparing aromatic compounds
|
|
JP3131574B2
(ja)
|
1996-09-04 |
2001-02-05 |
新日本製鐵株式会社 |
新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
|
|
US5939098A
(en)
|
1996-09-19 |
1999-08-17 |
Schering Corporation |
Cancer treatment with temozolomide
|
|
US5922683A
(en)
|
1997-05-29 |
1999-07-13 |
Abbott Laboratories |
Multicyclic erythromycin derivatives
|
|
MXPA00004919A
(es)
|
1997-11-21 |
2002-10-17 |
Euro Celtique Sa |
2-aminoacetamidas sustituidas y uso de las mismas.
|
|
BR9908207A
(pt)
|
1998-01-29 |
2000-11-28 |
Aventis Pharm Prod Inc |
Processo para preparar um composto de n- [ ( (alifático ou aromático) carbonil] -2-aminoacetamida, e, isonitrila ligada à resina
|
|
US7141603B2
(en)
|
1999-02-19 |
2006-11-28 |
The Regents Of The University California |
Antitumor agents
|
|
US6069146A
(en)
|
1998-03-25 |
2000-05-30 |
The Regents Of The University Of California |
Halimide, a cytotoxic marine natural product, and derivatives thereof
|
|
WO1999050245A1
(en)
|
1998-03-26 |
1999-10-07 |
Shionogi & Co., Ltd. |
Indole derivatives with antiviral activity
|
|
US6509331B1
(en)
|
1998-06-22 |
2003-01-21 |
Elan Pharmaceuticals, Inc. |
Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
|
|
FR2784988B1
(fr)
|
1998-10-23 |
2002-09-20 |
Adir |
Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US6358957B1
(en)
|
1998-11-12 |
2002-03-19 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
US7026322B2
(en)
|
1998-11-12 |
2006-04-11 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
AU784062B2
(en)
|
1999-08-23 |
2006-01-19 |
Dana-Farber Cancer Institute, Inc. |
Novel B7-4 molecules and uses therefor
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
AU782917C
(en)
|
2000-01-18 |
2006-11-23 |
Beyondspring Pharmaceuticals, Inc. |
Cell division inhibitors and process for producing the same
|
|
US6649172B2
(en)
|
2000-03-17 |
2003-11-18 |
Corixa Corporation |
Amphipathic aldehydes and their uses as adjuvants and immunoeffectors
|
|
HUP0302358A3
(en)
|
2000-05-09 |
2007-09-28 |
Adpharma |
Piperazinedione compounds and use of them for producing pharmaceutical compositions
|
|
JP2004518731A
(ja)
|
2000-12-28 |
2004-06-24 |
ニューロクライン バイオサイエンシーズ， インコーポレイテッド |
三環式ｃｒｆレセプターアンタゴニスト
|
|
US20030082140A1
(en)
|
2001-08-20 |
2003-05-01 |
Fisher Paul B. |
Combinatorial methods for inducing cancer cell death
|
|
US20040176372A1
(en)
|
2002-03-01 |
2004-09-09 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
AU2003244646B2
(en)
|
2002-05-17 |
2008-08-07 |
Aventis Pharma S.A. |
Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
|
|
US7012100B1
(en)
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
|
US7064201B2
(en)
|
2002-08-02 |
2006-06-20 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
CN101633655B
(zh)
*
|
2002-08-02 |
2014-04-30 |
大连万春药业有限公司 |
脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
|
|
US7919497B2
(en)
|
2002-08-02 |
2011-04-05 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
US7935704B2
(en)
|
2003-08-01 |
2011-05-03 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
WO2005077940A1
(en)
|
2004-02-04 |
2005-08-25 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
CN1934101B
(zh)
*
|
2004-02-04 |
2011-10-12 |
尼瑞斯药品公司 |
脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
|
|
PL1740593T3
(pl)
|
2004-04-19 |
2016-09-30 |
|
Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
|
|
DE202004018940U1
(de)
|
2004-12-07 |
2006-04-13 |
Asf Verwaltungs Gmbh |
Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
|
|
JP4559240B2
(ja)
|
2005-01-13 |
2010-10-06 |
株式会社エヌ・ティ・ティ・ドコモ |
移動通信システム、無線基地局、無線回線制御局及び電力制御方法
|
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
WO2007035841A1
(en)
|
2005-09-21 |
2007-03-29 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
KR20080089489A
(ko)
|
2006-01-18 |
2008-10-06 |
메르크 파텐트 게엠베하 |
인테그린 리간드를 사용하는 암치료용 특이적 요법
|
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US8129527B2
(en)
*
|
2006-11-03 |
2012-03-06 |
Nereus Pharmacuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
ES2527412T3
(es)
|
2007-02-15 |
2015-01-23 |
Mannkind Corporation |
Método para aumentar la respuesta de los linfocitos T
|
|
JP5641927B2
(ja)
|
2007-04-13 |
2014-12-17 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
Ｓｐａｒｃ及びその使用方法
|
|
US20090170837A1
(en)
|
2007-08-17 |
2009-07-02 |
Thallion Pharmaceuticals Inc. |
Methods for treating ras driven cancer in a subject
|
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
|
KR20100100949A
(ko)
|
2008-01-08 |
2010-09-15 |
브리스톨-마이어스 스큅 컴퍼니 |
증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
PT2376535T
(pt)
|
2008-12-09 |
2017-06-23 |
Hoffmann La Roche |
Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
|
|
EP2387420A2
(en)
|
2009-01-16 |
2011-11-23 |
Teva Pharmaceutical Industries Limited |
New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
|
|
WO2010114922A1
(en)
|
2009-03-31 |
2010-10-07 |
Agios Pharmaceuticals, Inc. |
Methods of treating cancer having an aberrant egfr or kras genotype
|
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
|
PL2464218T3
(pl)
|
2009-08-10 |
2015-12-31 |
Univ Texas |
Leczenie przerzutów do mózgu z zastosowaniem inhibitorów receptorów endoteliny w skojarzeniu z cytotoksycznym środkiem chemioterapeutycznym
|
|
US20110160159A1
(en)
|
2009-09-15 |
2011-06-30 |
John Ryan |
Treatment of cancer
|
|
MX2012004721A
(es)
|
2009-10-23 |
2012-06-25 |
Mannkind Corp |
Inmunoterapia de cancer y metodo de tratamiento.
|
|
WO2011066389A1
(en)
|
2009-11-24 |
2011-06-03 |
Medimmmune, Limited |
Targeted binding agents against b7-h1
|
|
CN101766815B
(zh)
|
2009-12-31 |
2012-04-25 |
胡松华 |
紫杉醇及多西紫杉醇的用途
|
|
EP2542699A4
(en)
|
2010-03-03 |
2013-10-02 |
Targeted Molecular Diagnostics Llc |
METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
|
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
US20130131018A1
(en)
|
2010-06-04 |
2013-05-23 |
Exonhit S.A. |
Substituted isoquinolines and their use as tubulin polymerization inhibitors
|
|
JP2012033526A
(ja)
|
2010-07-28 |
2012-02-16 |
Fuji Electric Co Ltd |
薄膜太陽電池およびその製造方法
|
|
WO2012035436A1
(en)
|
2010-09-15 |
2012-03-22 |
Tokyo University Of Pharmacy And Life Sciences |
Plinabulin prodrug analogs and therapeutic uses thereof
|
|
WO2012074904A2
(en)
|
2010-11-29 |
2012-06-07 |
Precision Therapeutics, Inc. |
Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
|
|
TWI386203B
(zh)
|
2011-01-07 |
2013-02-21 |
Univ China Medical |
治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
|
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
|
CN104024851A
(zh)
|
2011-11-28 |
2014-09-03 |
加拿大国家研究委员会 |
针对癌症的紫杉醇反应标志物
|
|
WO2013090552A1
(en)
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
DK2846809T3
(da)
|
2012-05-09 |
2021-01-18 |
Cantex Pharmaceuticals Inc |
Behandling af myelosuppression
|
|
AU2013204313C1
(en)
|
2012-06-01 |
2016-04-07 |
Bionomics Limited |
Combination Therapy
|
|
WO2014066834A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
MX374929B
(es)
|
2013-02-20 |
2025-03-06 |
Novartis Ag |
RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
|
|
AU2014244083B2
(en)
|
2013-03-13 |
2018-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
EP2988668B1
(en)
|
2013-04-24 |
2019-07-24 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
SG11201509742QA
(en)
|
2013-06-03 |
2015-12-30 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
US10596169B2
(en)
*
|
2013-10-11 |
2020-03-24 |
Beyondspring Inc. |
Cancer treatment with combination of plinabulin and taxane
|
|
EP4461372A3
(en)
|
2013-11-05 |
2025-01-22 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
EP3594359B1
(en)
|
2013-11-06 |
2022-05-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Method for subtyping lymphoma types by means of expression profiling
|
|
CN104796448B
(zh)
|
2014-01-22 |
2019-02-12 |
腾讯科技（深圳）有限公司 |
网络系统的数据处理方法和装置
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
CN106794246B
(zh)
|
2014-08-08 |
2021-10-15 |
OncoQuest制药有限公司 |
肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
|
|
CA2975729A1
(en)
|
2015-02-12 |
2016-08-18 |
Beyondspring Pharmaceuticals, Inc. |
Use of plinabulin in combination with immune checkpoint inhibitors
|
|
RU2736045C2
(ru)
|
2015-03-06 |
2020-11-11 |
Бейондспринг Фармасьютикалс, Инк. |
Способ лечения рака, ассоциированного с мутацией ras
|
|
US10076518B2
(en)
|
2015-03-06 |
2018-09-18 |
Beyondspring Pharmaceuticals, Inc. |
Method of treating a brain tumor
|
|
WO2016165007A1
(en)
|
2015-04-17 |
2016-10-20 |
The University Of British Columbia |
Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
|
|
CA2991059C
(en)
|
2015-07-13 |
2024-01-16 |
Beyondspring Pharmaceuticals, Inc. |
Plinabulin monohydrate polymorphs
|
|
CA2996426A1
(en)
|
2015-10-05 |
2017-04-13 |
Cedars-Sinai Medical Center |
Method of classifying and diagnosing cancer
|
|
SG11201806583XA
(en)
|
2016-02-08 |
2018-09-27 |
Beyondspring Pharmaceuticals Inc |
Compositions containing tucaresol or its analogs
|
|
US11229642B2
(en)
|
2016-06-06 |
2022-01-25 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method for reducing neutropenia
|
|
JP2020503363A
(ja)
|
2017-01-06 |
2020-01-30 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
チューブリン結合化合物およびその治療的使用
|
|
MY201811A
(en)
|
2017-02-01 |
2024-03-19 |
Beyondspring Pharmaceuticals Inc |
Method of reducing neutropenia
|
|
JP7280192B2
(ja)
|
2017-03-13 |
2023-05-23 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
プリナブリン組成物及びその使用
|
|
AU2019212118A1
(en)
|
2018-01-24 |
2020-09-03 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method for reducing thrombocytopenia via the administration of plinabulin
|
|
CN112105363A
(zh)
|
2018-02-01 |
2020-12-18 |
大连万春布林医药有限公司 |
用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
|
|
JP7500438B2
(ja)
|
2018-06-01 |
2024-06-17 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
|
|
MX2021001762A
(es)
|
2018-08-16 |
2021-04-19 |
Beyondspring Pharmaceuticals Inc |
Metodo y composicion para estimular la respuesta inmunitaria.
|